Moderna's stock doubles on promising cancer-vaccine results
The vaccine candidate, developed with Merck, is an mRNA therapy paired with the cancer drug Keytruda. It helped melanoma patients live longer in a late-stage trial, marking the first Phase 3 data for the experimental vaccine.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Regulatory Landscape and Exchange Policies for Virtual Currencies in Mainland China
-
2
Bitcoin (BTC): Latest Updates and Market Analysis of Digital Gold
-
3
The Deep Integration and Development of USDC with Crypto Lending Platforms
-
4
Cerebras's pre-market stock rose 6% after OpenAI CEO Altman called Cerebras a "close partner."
-
5
Cryptocurrency Information Platforms and Software Download Guide: Secure Access to Industry News and Trading Tools
-
6
Litecoin's price has recently surged: Can ETF applications and halving expectations sustain its rally?
-
7
Ethereum: Market Impact, Technological Advancements, and Future Outlook
-
8
Multiple U.S. states will vote on wealth taxes in November, with California potentially imposing a 5% net worth tax on billionaires.
-
9
Decoding the Connection Mechanism of Bitcoin Private Keys, Public Keys, and Wallet Addresses
-
10
STEEM Coin Analysis: The Current Status and Development Challenges of a Decentralized Social Blockchain
Markets Today
Recommended Reading










